The global pharmaceutical and biotech industry continues to unveil new drug potentials and challenges. Last week, key clinical trial results were announced, showcasing both advancements and disappointments. While some oncology and rare disease treatments showed promise, others failed to meet expectations.

On January 16, Boehringer Ingelheim terminated its Phase 3 "CONNEX" trial, which aimed to improve cognitive function in schizophrenia patients, citing a failure to achieve efficacy. In contrast, Novo Nordisk's obesity drug Wegovy (semaglutide) demonstrated significant weight loss benefits in its Phase 3 "STEP UP" trial, bolstering its potential. As these developments unfold, here is a closer look at last week’s most notable biotech updates.

On January 13, Regeneron Pharmaceuticals announced that its PD-1 inhibitor, Libtayo (cemiplimab), met its primary endpoint in a Phase 3 trial for adjuvant therapy in cutaneous squamous cell carcinoma (CSCC). The treatment reduced the risk of recurrence or death by 68% compared to placebo (HR: 0.32; 95% CI: 0.20-0.51, p<0.0001).

With no approved adjuvant therapy for CSCC, these findings highlight Libtayo’s potential to redefine treatment standards. Regeneron emphasized its superiority over Keytruda (pembrolizumab), which failed a similar trial, reinforcing Libtayo’s position as the new standard of care.

On the same day, Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics released topline results from their Phase 2 obesity trial of HRS9531, a GLP-1/GIP dual agonist. Patients receiving an 8 mg weekly subcutaneous dose achieved a mean weight reduction of 21.1% at 36 weeks compared to placebo (p<0.0001). The treatment maintained continuous weight loss, with 59% of patients experiencing at least a 20% reduction. These promising results set the stage for further clinical evaluation.

On January 14, Sling Therapeutics reported that its Phase 2b/3 LIDS trial of Linsitinib demonstrated a 52% reduction in proptosis among thyroid eye disease (TED) patients. Unlike current intravenous treatments, Linsitinib’s oral formulation offers a more convenient alternative. The drug also avoided common side effects like hearing loss and hyperglycemia, positioning it as a competitive option in the TED market.

Meanwhile, Vistagen presented positive data from a Phase 2A study of PH284, a pherine-class nasal spray targeting appetite loss in cancer cachexia patients. Patients receiving PH284 experienced a 71% increase in subjective hunger levels by day seven, compared to less than 1% in the placebo group. Despite these encouraging results, Vistagen’s stock declined by 3.07%.

On January 15, Zai Lab reported positive Chinese subgroup data from the Phase 3 "innovaTV 301" trial of TIVDAK for recurrent or metastatic cervical cancer. The drug reduced the risk of death by 45% compared to chemotherapy (HR: 0.55, 95% CI: 0.27-1.15). The median overall survival (OS) had not been reached for TIVDAK-treated patients, whereas chemotherapy patients had a median OS of 10.7 months. These findings will support Zai Lab’s regulatory submission in China.

That same day, Inflammasome Therapeutics announced promising three-month trial results for its K8 implant in geographic atrophy (GA). Among five bilateral GA patients, the treated eye showed a 66% slower lesion growth rate than the untreated eye (p = 0.029). With no reported drug-related adverse effects, the company plans to expand the trial to 30 patients.

OS Therapies also reported success in its Phase 2b trial of OST-HER2 for pulmonary metastatic osteosarcoma. The therapy met its primary endpoint, improving 12-month event-free survival (EFS) to 33% compared to a historical control rate of 20% (p = 0.0158). Positive trends were also noted in overall survival at one and two years.

However, not all developments were positive. Keros Therapeutics suspended its Phase 2 TROPOS trial of cibotercept for pulmonary arterial hypertension (PAH) after multiple cases of pericardial effusion. This follows an earlier decision to halt high-dose arms in December 2024 due to similar safety concerns. The latest suspension triggered a 16.51% drop in Keros’ stock.

On January 16, Avacta Therapeutics announced encouraging Phase 1 trial data for AVA6000 in salivary gland cancer. The peptide drug conjugate (PDC), designed to activate selectively in tumors, demonstrated a 90% disease control rate. Among ten patients, tumor shrinkage was observed in five, with one achieving a partial response (45% tumor reduction). Avacta has initiated a Phase 1b expansion trial targeting multiple cancer types, including triple-negative breast cancer and soft tissue sarcoma.

On the same day, Outlook Therapeutics released 12-week data from its Phase 3 NORSE EIGHT trial of ONS-5010 for wet age-related macular degeneration (AMD). The therapy showed non-inferiority to Lucentis (ranibizumab), with patients gaining 5.5 letters in best-corrected visual acuity (BCVA), compared to 6.5 letters for Lucentis. However, the trial did not meet its non-inferiority endpoint at eight weeks, leading to uncertainty despite sustained visual improvement at 12 weeks.

As these developments unfold, the biotech industry remains a landscape of breakthroughs and challenges, where each success paves the way for new treatments while setbacks refine future strategies.